menatetranone + alfacalcidol
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopausal Osteoporosis
Conditions
Postmenopausal Osteoporosis
Trial Timeline
May 1, 2005 → Jul 1, 2007
NCT ID
NCT00165698About menatetranone + alfacalcidol
menatetranone + alfacalcidol is a phase 3 stage product being developed by Eisai for Postmenopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00165698. Target conditions include Postmenopausal Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00165698 | Phase 3 | Completed |
Competing Products
20 competing products in Postmenopausal Osteoporosis